אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - epoetin alfa, quantity: 2000 iu/ml - injection, solution - excipient ingredients: glycine; sodium chloride; dibasic sodium phosphate dihydrate; water for injections; polysorbate 80; monobasic sodium phosphate - eprex is indicated for the treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions. eprex is also indicated for the treatment of anaemia and reduction of transfusion in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy. eprex is also indicated in adult patients with mild- to-moderate anaemia (haemoglobin > 100 to <= 130 g/l) scheduled for elective surgery with an expected moderate blood loss (2-4 units or 900 to 1800 ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery. eprex is also indicated to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to pre-deposit their complete peri-operative blood needs

ארצות הברית - אנגלית - NLM (National Library of Medicine)

stat rx usa - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7), ibuprofen (unii: wk2xyi10qm) (ibuprofen - unii:wk2xyi10qm) - hydrocodone bitartrate 5 mg - carefully consider the potential benefits and risks of reprexain™ and other treatment options before deciding to use reprexain™. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). reprexain™ tablets are indicated for the short-term (generally less than 10 days) management of acute pain. reprexain™ is not indicated for the treatment of such conditions as osteoarthritis or rheumatoid arthritis. reprexain™ is contraindicated in patients with known hypersensitivity to hydrocodone or ibuprofen. patients known to be hypersensitive to other opioids may exhibit cross-sensitivity to hydrocodone. reprexain™ should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings – anaphylactoid reactions, and precautions - pre-existing asthma ). reprexain™ i

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoetin alfa 84 µg/ml (human recombinant erythropoietin (r-huepo cho)) - solution for injection - 10000 iu/ml - active: epoetin alfa 84 µg/ml (human recombinant erythropoietin (r-huepo cho)) excipient: dibasic sodium phosphate dihydrate glycine monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride water for injection - eprex is indicated for: · the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients with renal insufficiency not yet undergoing dialysis. · anaemia associated with chronic renal failure in paediatric and adult patients on dialysis. · anaemia in patients with non-myeloid malignancies where anaemia is due to the effect of concomitantly administered chemotherapy. · adult patients with mild-to-moderate anaemia (haemoglobin > 100 to < 130g/l) scheduled for elective surgery with an expected moderate blood loss (2-4 units or 900 to 1800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery. · to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients undergoing major surgery who are not expected to pre-deposit their complete peri-operative blood needs.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoetin alfa 16.8 µg/ml (human recombinant erythropoietin(r-huepo cho)) - solution for injection - 2000 iu/ml - active: epoetin alfa 16.8 µg/ml (human recombinant erythropoietin(r-huepo cho)) excipient: dibasic sodium phosphate dihydrate glycine monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride water for injection - eprex is indicated for: · the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients with renal insufficiency not yet undergoing dialysis. · anaemia associated with chronic renal failure in paediatric and adult patients on dialysis. · anaemia in patients with non-myeloid malignancies where anaemia is due to the effect of concomitantly administered chemotherapy. · adult patients with mild-to-moderate anaemia (haemoglobin > 100 to < 130g/l) scheduled for elective surgery with an expected moderate blood loss (2-4 units or 900 to 1800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery. · to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients undergoing major surgery who are not expected to pre-deposit their complete peri-operative blood needs.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoetin alfa 336 µg/ml (human recombinant erythropoietin) - solution for injection - 40000 iu/ml - active: epoetin alfa 336 µg/ml (human recombinant erythropoietin) excipient: dibasic sodium phosphate dihydrate glycine monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride water for injection - eprex is indicated for: · the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients with renal insufficiency not yet undergoing dialysis. · anaemia associated with chronic renal failure in paediatric and adult patients on dialysis. · anaemia in patients with non-myeloid malignancies where anaemia is due to the effect of concomitantly administered chemotherapy. · adult patients with mild-to-moderate anaemia (haemoglobin > 100 to < 130g/l) scheduled for elective surgery with an expected moderate blood loss (2-4 units or 900 to 1800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery. · to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients undergoing major surgery who are not expected to pre-deposit their complete peri-operative blood needs.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoetin alfa 336 µg/ml - solution for injection - 40000 iu/ml - active: epoetin alfa 336 µg/ml excipient: dibasic sodium phosphate dihydrate glycine monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride water for injection - eprex is indicated for: · the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients with renal insufficiency not yet undergoing dialysis. · anaemia associated with chronic renal failure in paediatric and adult patients on dialysis. · anaemia in patients with non-myeloid malignancies where anaemia is due to the effect of concomitantly administered chemotherapy. · adult patients with mild-to-moderate anaemia (haemoglobin > 100 to < 130g/l) scheduled for elective surgery with an expected moderate blood loss (2-4 units or 900 to 1800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery. · to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients undergoing major surgery who are not expected to pre-deposit their complete peri-operative blood needs.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoetin alfa 33.6 µg/ml (human recombinant erythropoietin(r-huepo cho)) - solution for injection - 4000 iu/ml - active: epoetin alfa 33.6 µg/ml (human recombinant erythropoietin(r-huepo cho)) excipient: dibasic sodium phosphate dihydrate glycine monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride water for injection - eprex is indicated for: · the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients with renal insufficiency not yet undergoing dialysis. · anaemia associated with chronic renal failure in paediatric and adult patients on dialysis. · anaemia in patients with non-myeloid malignancies where anaemia is due to the effect of concomitantly administered chemotherapy. · adult patients with mild-to-moderate anaemia (haemoglobin > 100 to < 130g/l) scheduled for elective surgery with an expected moderate blood loss (2-4 units or 900 to 1800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery. · to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients undergoing major surgery who are not expected to pre-deposit their complete peri-operative blood needs.

ישראל - אנגלית - Ministry of Health

j-c health care ltd - recombinant human erythropoietin - solution for injection - recombinant human erythropoietin 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. eprex is not indicated for anemic patients who are willing to donate autologous blood. the safety of the perioperative use of eprex has been studied only in patients who are receiving anticoagulant prophylaxis. eprex is indicated before surgerios known be associated with excessive blood loss (at least 2 units ).

ישראל - אנגלית - Ministry of Health

j-c health care ltd - recombinant human erythropoietin - solution for injection - recombinant human erythropoietin 2000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. eprex is not indicated for anemic patients who are willing to donate autologous blood. the safety of the perioperative use of eprex has been studied only in patients who are receiving anticoagulant prophylaxis. eprex is indicated before surgerios known be associated with excessive blood loss (at least 2 units ).

ישראל - אנגלית - Ministry of Health

j-c health care ltd - recombinant human erythropoietin - solution for injection - recombinant human erythropoietin 4000 iu / 0.4 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. eprex is not indicated for anemic patients who are willing to donate autologous blood. the safety of the perioperative use of eprex has been studied only in patients who are receiving anticoagulant prophylaxis. eprex is indicated before surgerios known be associated with excessive blood loss (at least 2 units ).